This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Should First Trust Small Cap Growth AlphaDEX Fund (FYC) Be on Your Investing Radar?
by Sweta Killa
Style Box ETF report for FYC
Pharma Stock Roundup: PTCT Unveils Promising Data, RHHBY to Acquire Rest of FMI
by Zacks Equity Research
Roche (RHHBY) will buy the remaining stake in Foundation Medicine for $2.4 billion. PTC Therapeutics (PTCT) presents encouraging preliminary data from an early-stage study in spinal muscular atrophy.
TESARO (TSRO) Stock Up on Rumors of Buyout Offer From Roche
by Zacks Equity Research
Shares of TESARO (TSRO) rise on speculation of an acquisition bid from Roche.
Will Roche's (RHHBY) Acquisition Spree Revive the Top Line?
by Zacks Equity Research
Roche (RHHBY) is looking to boost its portfolio with some strategic acquisitions and we expect further activities on this front.
Company News For Jun 20, 2018
by Zacks Equity Research
Companies in the news are: T,FMI,COTV,SRPT
Roche to Buy Rest of Foundation Medicine for $2.4 billion
by Zacks Equity Research
Roche inks a deal with Foundation Medicine to acquire the remaining shares of Foundation Medicine, not already owned by it for a total consideration of $2.4 billion.
5 Top Performing Stocks of the Best ETF of May
by Sweta Killa
Inside the best performing stocks of the top ETF of May - ARKG.
Company News For Dec 5, 2017
by Zacks Equity Research
Companies In The News are: AET,BGC,CVS,FMI,EXAC
Options Traders Expect Huge Moves in Foundation Medicine (FMI) Stock
by Zacks Equity Research
Investors in Foundation Medicine (FMI) need to pay close attention to the stock based on moves in the options market lately.
ETF Winner of 1H17 and its Top 5 Stocks
by Sweta Killa
Inside the top performing ETF of the first half of 2017.
Foundation Medicine (FMI) Jumps: Stock Adds 10.6% in Session
by Zacks Equity Research
Foundation Medicine, Inc. (FMI) moved big last session, as its shares rose over 10% on the day.
Is the Options Market Predicting a Spike in Foundation Medicine (FMI) Stock?
by Zacks Equity Research
Investors in Foundation Medicine, Inc. (FMI) need to pay close attention to the stock based on moves in the options market lately.
Implied Volatility Surging for Foundation Medicine (FMI) Stock Options
by Zacks Equity Research
Options traders are pricing in a big move for Foundation Medicine (FMI) shares as it has huge implied volatility.
What's Behind Clovis' (CLVS) One-Year Rally of 146.3%?
by Zacks Equity Research
In December, Clovis received the FDA nod for its first product, Rubraca, which sent its shares soaring.
Foundation Medicine (FMI): Moving Average Crossover Alert
by Zacks Equity Research
Foundation Medicine, Inc. (FMI) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
Clovis Scales 52-Week High on Early FDA Nod for Rubraca
by Zacks Equity Research
Shares of Clovis Oncology (CLVS) touched a 52-week high after the company gained accelerated FDA nod for its advanced ovarian cancer drug, Rubraca.